@ISNeducation Webinar: Monoclonal Gammopathy of Renal Significance — Clinical Perspective
Monoclonal gammopathy of renal significance (MGRS) is an emergent entity describing the presence of kidney damage together with any plasma cell or B cell clonal proliferation, which are shown by paraproteinemia assays without full criteria of cancer. Glomerular involvement is the most common presentation. Tubular, tubulointerstitial and vascular involvements are also seen in the MGRS spectrum. MGRS lesions are monoclonal immunoglobulin deposition disease, proliferative glomerulonephritis (GN), AL amyloidosis, fibrillary GN, immunotactoid GN and cryoglobulinemic GN. Light chain proximal tubulopathy, C3 GN and TMA are also described in MGRS lesions. Determination of responsible clones is crucial before planning specific treatment of MGRS. Bortezomib and Rituximab are the most commonly used agents. Primary goals in the MGRS treatment are preservation of kidney functions, preventing posttransplantation recurrence and limiting the extra-renal manifestations.
1. To identify the definition of MGRS
2. To learn the diagnostic tools (laboratory and kidney biopsy findings) for
3. To learn MGRS management with the nephrologist perspective